Shares of other companies:
April 24, 2024 Google’s Third Cookie Phaseout Delay Amid Regulatory Hurdles
April 19, 2024 Bitcoin Halving: Catalyst for New Price Heights?
April 18, 2024 EU Moves Toward Single Capital Market Union
Amazon: The Margin Train Is Gaining Speed
April 24, 2024
Amazon Web Services Expands Bedrock GenAI Service
April 23, 2024
Why Microsoft Stands Out As A Pre-Earnings Buy
April 23, 2024
Wall Street Lunch: Big Tech Bearishness?
April 22, 2024
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
April 12, 2024 Improve Your Financial Status: A How-To Guide
Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
EW Stock News and Mentions of Edwards Lifesciences Corp. Stocktwits
Updated: April 25, 2024 (13:15)
Sector: Healthcare
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where Edwards Lifesciences Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of Edwards Lifesciences Corp. (EW).
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the Edwards Lifesciences stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of Edwards Lifesciences Corp. (EW)
April 24, 2024 (17:56) / "Zacks Commentary" (by Urmimala Biswas)
Watch These 3 MedTech Stocks This Earnings Season: Beat or Miss?
Here is a sneak peek into how the three major MedTech stocks, LH, EW and RMD, are expected to fare in their quarterly results slated to be released tomorrow.
In Article Trend: Somewhat-Bullish
April 24, 2024 (15:34) / "Zacks Commentary" (by Zacks Equity Research)
Rising Demand Likely to Aid GE HealthCare's ( GEHC ) Q1 Earnings
GE HealthCare's (GEHC) first-quarter results are expected to report strong organic revenue growth, banking on balanced segmental performance driven by consistent NPIs and growing customer demand.
In Article Trend: Bullish
April 24, 2024 (10:25) / "Zacks Commentary" (by Zacks Equity Research)
Ongoing Procedural Growth May Aid Stryker's ( SYK ) Q1 Earnings
Stryker's (SYK) first-quarter 2024 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued to hurt margins.
In Article Trend: Somewhat-Bullish
April 23, 2024 (13:29) / "Zacks Commentary" (by Zacks Equity Research)
DexCom ( DXCM ) to Report Q1 Earnings: What's in the Cards?
DexCom's (DXCM) first-quarter 2024 results are likely to reflect rising volumes across all channels.
In Article Trend: Somewhat-Bullish
April 22, 2024 (13:44) / "Zacks Commentary" (by Zacks Equity Research)
Is a Beat Likely for West Pharmaceutical ( WST ) in Q1 Earnings?
West Pharmaceutical's (WST) first-quarter 2024 results are likely to reflect strength in its Proprietary Products business. However, unfavorable currency movements might have hurt the top and bottom lines.
In Article Trend: Neutral
April 22, 2024 (13:16) / "Zacks Commentary" (by Zacks Equity Research)
Unveiling Edwards Lifesciences ( EW ) Q1 Outlook: Wall Street Estimates for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Edwards Lifesciences (EW), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.
In Article Trend: Somewhat-Bullish
April 19, 2024 (18:00) / "Zacks Commentary" (by Zacks Equity Research)
Will Acute Care Unit Aid Universal Health's ( UHS ) Q1 Earnings?
Universal Health's (UHS) Q1 results are expected to be aided by growing patient volumes and surgical cases, partly offset by increased expenses.
In Article Trend: Somewhat-Bullish
April 19, 2024 (15:30) / "Zacks Commentary" (by Zacks Equity Research)
Hologic ( HOLX ) Q2 Earnings Might Rise on GYN Surgical Growth
Hologic's (HOLX) second-quarter fiscal 2024 performance is likely to be driven by the GYN Surgical portfolio.
In Article Trend: Somewhat-Bullish
April 19, 2024 (14:24) / "Zacks Commentary" (by Zacks Equity Research)
Will Humana ( HUM ) Q1 Earnings Beat on CenterWell Strength?
Humana's (HUM) first-quarter results are likely to reflect rising premiums and investment income.
In Article Trend: Somewhat-Bullish
April 19, 2024 (11:46) / "Zacks Commentary" (by Nalak Das)
5 Large-Cap Medical Stocks to Buy Ahead of Q1 Earnings
We have narrowed our search to five S&P 500 medical stocks that are poised to beat on first-quarter earnings results.These are: HCA, UHS, LH, EW, PODD.
In Article Trend: Bullish
April 19, 2024 (11:28) / "Zacks Commentary" (by Zacks Equity Research)
Will High Medical Care Ratios Hurt Molina's ( MOH ) Q1 Earnings?
Molina's (MOH) first-quarter performance is likely to have been hurt by escalating medical care costs, partly offset by growing membership in all three businesses.
In Article Trend: Somewhat-Bullish
April 18, 2024 (20:32) / "Benzinga" (by Benzinga Insights)
Behind the Scenes of Edwards Lifesciences's Latest Options Trends - Edwards Lifesciences ( NYSE:EW )
Whales with a lot of money to spend have taken a noticeably bearish stance on Edwards Lifesciences. Looking at options history for Edwards Lifesciences EW we detected 8 trades. If we consider the specifics of each trade, it is accurate to state that 12% of the investors opened trades with ...
In Article Trend: Neutral
April 18, 2024 (15:14) / "Zacks Commentary" (by Zacks Equity Research)
Will Low Patient Days Impact Community Health ( CYH ) Q1 Earnings?
Community Health's (CYH) first-quarter results are likely to reflect declining beds in services and adjusted admissions.
In Article Trend: Neutral
April 18, 2024 (14:03) / "Zacks Commentary" (by Zacks Equity Research)
Bio-Rad Laboratories ( BIO ) to Post Q1 Earnings: What Awaits?
The ongoing weakness in the biopharma end markets and tightening of sanctions against Russia is likely to have hurt Bio-Rad's (BIO) first-quarter 2024 growth.
In Article Trend: Neutral
April 18, 2024 (14:01) / "Zacks Commentary" (by Zacks Equity Research)
Edwards Lifesciences ( EW ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Edwards Lifesciences (EW) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In Article Trend: Somewhat-Bullish
April 17, 2024 (15:01) / "Zacks Commentary" (by Zacks Equity Research)
Is a Beat Likely for Edwards Lifesciences ( EW ) in Q1 Earnings?
The strong adoption of transcatheter heart valves is expected to have led to Edwards Lifesciences' (EW) growth in the first quarter.
In Article Trend: Bullish
April 17, 2024 (15:01) / "Zacks Commentary" (by Zacks Equity Research)
Hologic ( HOLX ) to Report Q2 Earnings: What's in the Cards?
Strength in Molecular Diagnostics business and GYN Surgical is likely to have driven Hologic's (HOLX) fiscal second-quarter performance.
In Article Trend: Somewhat-Bullish
April 16, 2024 (18:04) / "Zacks Commentary" (by Zacks Equity Research)
Is a Beat Likely for Intuitive Surgical ( ISRG ) in Q1 Earnings?
Intuitive Surgical's (ISRG) first-quarter results are likely to reflect solid performance in the Instruments & Accessories segment. However, rising costs might have hurt margins.
In Article Trend: Somewhat-Bullish
April 16, 2024 (17:25) / "Zacks Commentary" (by Zacks Equity Research)
UnitedHealth Group ( UNH ) Tops on Q1 Earnings, Reaffirms EPS View
UnitedHealth Group (UNH) first-quarter earnings benefit from strong Optum and UnitedHealthcare business lines. Rising expenses partially offset the positives.
In Article Trend: Neutral
April 16, 2024 (15:51) / "Zacks Commentary" (by Zacks Equity Research)
Align Technology ( ALGN ) to Post Q1 Earnings: What's in Store?
Align Technology's (ALGN) first-quarter 2024 performance is likely to reflect the strength of the Clear Aligner and Systems & Services businesses.
In Article Trend: Somewhat-Bullish
April 16, 2024 (15:40) / "Zacks Commentary" (by Zacks Equity Research)
ITGR vs. EW: Which Stock Should Value Investors Buy Now?
ITGR vs. EW: Which Stock Is the Better Value Option?
In Article Trend: Bullish
April 16, 2024 (14:44) / "Zacks Commentary" (by Zacks Equity Research)
What's in Store for Boston Scientific ( BSX ) in Q1 Earnings?
Boston Scientific (BSX) is expected to have registered strong growth in the Asia Pacific, led by strength in China, Japan and Latin America.
In Article Trend: Bullish
April 16, 2024 (08:34) / "Zacks Commentary" (by Zacks Investment Research)
Zacks Industry Outlook Highlights Edwards Lifesciences, DexCom and STERIS
Edwards Lifesciences, DexCom and STERIS have been highlighted in this Industry Outlook article.
In Article Trend: Neutral
April 15, 2024 (16:58) / "Zacks Commentary" (by Zacks Equity Research)
What's in Store for Thermo Fisher ( TMO ) in Q1 Earnings?
Strength in Analytical Instrument and Laboratory Products and Services segments are likely to have driven Thermo Fisher's (TMO) first-quarter 2024 performance.
In Article Trend: Somewhat-Bullish
April 15, 2024 (15:28) / "Zacks Commentary" (by Zacks Equity Research)
Will Elevance ( ELV ) Beat Q1 Earnings on Carelon Strength?
The first-quarter results of Elevance (ELV) are likely to reflect higher product revenues and Commercial Individual membership growth.
In Article Trend: Somewhat-Bullish
April 15, 2024 (15:16) / "Zacks Commentary" (by Urmimala Biswas)
3 Medical Instruments Stocks to Buy Amid Improving Industry Trends
The Zacks Medical - Instruments industry is expected to gain from the rising adoption of smart healthcare options, including genAI. However, supply issues and staffing shortages continue to disrupt growth. EW, DXCM and STE appear well-poised to brave the challenges.
In Article Trend: Neutral
April 12, 2024 (21:00) / "Benzinga" (by Benzinga Insights)
$1000 Invested In Edwards Lifesciences 15 Years Ago Would Be Worth This Much Today - Edwards Lifesciences ( NYSE:EW )
Edwards Lifesciences EW has outperformed the market over the past 15 years by 8.57% on an annualized basis producing an average annual return of 21.41%. Currently, Edwards Lifesciences has a market capitalization of $54.34 billion.
In Article Trend: Somewhat-Bullish
April 12, 2024 (16:20) / "Zacks Commentary" (by Zacks Equity Research)
Can High Medical Costs Affect UnitedHealth's ( UNH ) Q1 Earnings?
UnitedHealth's (UNH) first-quarter results are likely to reflect growth in premium levels and service revenues.
In Article Trend: Somewhat-Bullish
April 12, 2024 (15:45) / "Benzinga" (by Benzinga Insights)
How Is The Market Feeling About Edwards Lifesciences? - Edwards Lifesciences ( NYSE:EW )
Edwards Lifesciences's EW short percent of float has risen 24.11% since its last report. The company recently reported that it has 10.45 million shares sold short, which is 1.75% of all regular shares that are available for trading.
In Article Trend: Somewhat-Bullish
April 12, 2024 (13:51) / "Zacks Commentary" (by Zacks Equity Research)
What's in Store for Abbott Laboratories ( ABT ) in Q1 Earnings?
Abbott (ABT) is likely to have progressed with its initiative to commercialize several biosimilars in emerging markets.
In Article Trend: Somewhat-Bullish
April 11, 2024 (10:45) / "Benzinga" (by Zacks)
Boston Scientific ( BSX ) Faces Rising Costs, Competition - Boston Scientific ( NYSE:BSX ) , Cardinal Health ( NYSE:CAH )
Boston Scientific Corporation BSX has been struggling due to unfavorable currency movement and macroeconomic woes. Strong competitors in the large medical device market also pose a tough challenge for Boston Scientific. The stock carries a Zacks Rank #4 ( Sell ) currently.
In Article Trend: Neutral
April 10, 2024 (16:45) / "Zacks Commentary" (by Zacks Equity Research)
Will UnitedHealth's ( UNH ) UnitedHealthcare Unit Aid Q1 Earnings?
UnitedHealth's (UNH) first-quarter results are expected to benefit from an increase in UnitedHealthcare's Community & State revenues and the number of people it served.
In Article Trend: Somewhat-Bullish
April 10, 2024 (13:30) / "Zacks Commentary" (by Zacks Equity Research)
Boston Scientific ( BSX ) Faces Rising Costs, Competition
With Boston Scientific (BSX) recording 40% of its sales from the international market, it remains highly exposed to currency fluctuations.
In Article Trend: Neutral
April 9, 2024 (18:13) / "Zacks Commentary" (by Zacks Equity Research)
Elevance Health ( ELV ) Brand Inks Deal to Better Serve Georgia
Elevance Health's (ELV) brand, Anthem Blue Cross and Blue Shield, collaborates to make the benefits of Piedmont's healthcare network available to its members across specific Georgia regions.
In Article Trend: Somewhat-Bullish
April 7, 2024 (13:45) / "PR Newswire" (by Medtronic plc)
SMART trial one-year data demonstrates Medtronic Evolut™ TAVR platform as optimal treatment for severe aortic stenosis in patients with small annulus, which is primarily women
SMART trial one-year data demonstrates Medtronic Evolut™ TAVR platform as optimal treatment for severe aortic ... PR ...
In Article Trend: Somewhat-Bullish
April 7, 2024 (13:45) / "Canada Newswire" (by Medtronic plc)
SMART trial one-year data demonstrates Medtronic Evolut™ TAVR platform as optimal treatment for severe aortic stenosis in patients with small annulus, which is primarily women
SMART trial one-year data demonstrates Medtronic Evolut™ TAVR platform as optimal treatment for severe aortic ... Canada ...
In Article Trend: Somewhat-Bullish
April 3, 2024 (16:45) / "Zacks Commentary" (by Zacks Equity Research)
Tenet Healthcare ( THC ) Soars 76% in a Year: What Lies Ahead?
Tenet Healthcare (THC) remains well-poised for growth on increased admissions and surgeries in the Hospital segment, acquisitions, debt repayment efforts and solid operating cash flows.
In Article Trend: Somewhat-Bullish
March 28, 2024 (15:44) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why Investors Should Hold Teladoc ( TDOC ) Stock Now
Teladoc's (TDOC) Integrated Care business is expected to gain from margin expansion and improving chronic care program enrollment.
In Article Trend: Somewhat-Bullish
March 27, 2024 (12:30) / "Zacks Commentary" (by Zacks Equity Research)
If You Invested $1000 in Edwards Lifesciences a Decade Ago, This is How Much It'd Be Worth Now
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
In Article Trend: Bullish
March 26, 2024 (18:38) / "Benzinga" (by PRNewswire)
Academy Award® Winner Matthew McConaughey Narrates MacGillivray Freeman's 3D Documentary for IMAX® and Giant Screen Theaters "Superhuman Body: World of Medical Marvels"
Giant screen film celebrates the wonders of the human body and the scientific breakthroughs that are transforming human health when it opens in select theatres starting April 12
In Article Trend: Bullish
March 26, 2024 (12:40) / "Zacks Commentary" (by Zacks Equity Research)
Delcath Systems, Inc. ( DCTH ) Reports Q4 Loss, Tops Revenue Estimates
Delcath Systems (DCTH) delivered earnings and revenue surprises of 28.36% and 12.29%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
In Article Trend: Neutral
March 25, 2024 (13:40) / "Zacks Commentary" (by Zacks Equity Research)
Are Medical Stocks Lagging Edwards Lifesciences ( EW ) This Year?
Here is how Edwards Lifesciences (EW) and Avinger (AVGR) have performed compared to their sector so far this year.
In Article Trend: Somewhat-Bullish
March 22, 2024 (20:15) / "Benzinga" (by Benzinga Insights)
Behind the Scenes of Edwards Lifesciences's Latest Options Trends - Edwards Lifesciences ( NYSE:EW )
Investors with a lot of money to spend have taken a bullish stance on Edwards Lifesciences EW. We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.
In Article Trend: Somewhat-Bullish
March 22, 2024 (17:02) / "Zacks Commentary" (by Zacks Equity Research)
Compelling Reasons to Hold on to UnitedHealth Group ( UNH ) Stock
UnitedHealth Group (UNH) remains well-poised for growth on the back of improved premiums, acquisitions and partnerships, an in-demand telehealth services suite and solid cash-generating abilities.
In Article Trend: Bullish
March 20, 2024 (06:40) / "Stocknews.com" (by Defense World Staff)
Edwards Lifesciences ( NYSE:EW ) Downgraded by StockNews.com
Edwards Lifesciences ( NYSE:EW - Get Free Report ) was downgraded by research analysts at StockNews.com from a "buy" rating to a "hold" rating in a research report issued on Wednesday. A number of other equities analysts also recently weighed in on the stock.
In Article Trend: Somewhat-Bullish
March 19, 2024 (18:24) / "Investors Business Daily" (by JULIE MAK)
Edwards Lifesciences Stock Earns Relative Strength Rating Upgrade; Hits Key Benchmark
Edwards Lifesciences Stock Earns Relative Strength Rating Upgrade. Hits Key Benchmark Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
March 19, 2024 (17:38) / "Zacks Commentary" (by Zacks Equity Research)
Edwards Lifesciences ( EW ) Up 21.8% YTD: What's Driving It?
Investors are optimistic about Edwards Lifescience's (EW) substantial growth across each of its four product groups.
In Article Trend: Bullish
March 19, 2024 (08:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
Edwards Lifesciences Earns Relative Strength Rating Upgrade; Hits Key Benchmark
Edwards Lifesciences Earns Relative Strength Rating Upgrade. Hits Key Benchmark Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
March 15, 2024 (15:30) / "Zacks Commentary" (by Zacks Equity Research)
IQVIA ( IQV ) Up 5.3% Since Last Earnings Report: Can It Continue?
IQVIA (IQV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
In Article Trend: Neutral
March 15, 2024 (14:50) / "Zacks Commentary" (by Zacks Equity Research)
Edwards Lifesciences ( EW ) Hits 52-Week High: What's Driving It?
Edwards Lifesciences (EW) outperforms the industry, owing to a robust 2023 fourth-quarter performance, as well as the strong potential in the TMTT division.
In Article Trend: Somewhat-Bullish
March 14, 2024 (15:30) / "Benzinga" (by Benzinga Insights)
Here's How Much You Would Have Made Owning Edwards Lifesciences Stock In The Last 15 Years - Edwards Lifesciences ( NYSE:EW )
Edwards Lifesciences EW has outperformed the market over the past 15 years by 7.87% on an annualized basis producing an average annual return of 21.4%. Currently, Edwards Lifesciences has a market capitalization of $55.88 billion.
In Article Trend: Somewhat-Bullish
March 14, 2024 (13:48) / "Zacks Commentary" (by Nalak Das)
Buy 5 Medical Devices Stocks for a Stable Portfolio in 2024
We have narrowed our search to five Medical Instruments stocks with strong potential for 2024. These are: AORT, TMDX, DXCM, SWAV, EW.
In Article Trend: Bullish
March 14, 2024 (13:02) / "Zacks Commentary" (by Zacks Equity Research)
Zacks Investment Ideas feature highlights: Tenet Healthcare and HCA Healthcare
Tenet Healthcare and HCA Healthcare are part of the Zacks Investment Ideas article.
In Article Trend: Somewhat-Bullish
March 13, 2024 (16:38) / "Zacks Commentary" (by Bryan Hayes)
Medical Devices ETF Hits 52-Week High: Stocks to Watch
Historically viewed as a defensive area, health care also boasts many growth aspects and benefits from advances in technology.
In Article Trend: Somewhat-Bullish
March 13, 2024 (15:57) / "Zacks Commentary" (by Zacks Equity Research)
Edwards Lifesciences' ( EW ) SAPIEN TAVR Study Outcome Favorable
Edwards Lifesciences' (EW) recent study provides insights into the actual performance of small Edwards valves and reaffirms the excellent outcomes for patients receiving SAPIEN TAVR.
In Article Trend: Somewhat-Bullish
March 13, 2024 (07:14) / "Stocknews.com" (by ABMN Staff)
Edwards Lifesciences ( NYSE:EW ) Upgraded to Buy at StockNews.com
Edwards Lifesciences ( NYSE:EW ) Upgraded to Buy at ...
In Article Trend: Somewhat-Bullish
March 13, 2024 (07:12) / "Stocknews.com" (by Defense World Staff)
Edwards Lifesciences ( NYSE:EW ) Upgraded to "Buy" by StockNews.com
StockNews.com upgraded shares of Edwards Lifesciences ( NYSE:EW - Free Report ) from a hold rating to a buy rating in a research note released on Tuesday.
In Article Trend: Somewhat-Bullish
March 11, 2024 (12:30) / "Zacks Commentary" (by Zacks Equity Research)
Here's How Much a $1000 Investment in Edwards Lifesciences Made 10 Years Ago Would Be Worth Today
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
In Article Trend: Bullish
March 8, 2024 (08:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
Stocks To Watch: Edwards Lifesciences Sees RS Rating Jump To 87
Edwards Lifesciences ( EW ) saw a positive improvement to its Relative Strength ( RS ) Rating on Friday, with an upgrade from 80 to 87. X This exclusive rating from Investor's Business Daily tracks market leadership with a 1 ( worst ) to 99 ( best ) score.
In Article Trend: Bullish
March 7, 2024 (21:44) / "Investors Business Daily" (by Investor's Business Daily)
Futures Await Jobs Report; Nvidia Hasn't Done This In 20 Years
Futures Await Jobs Report. Nvidia Hasn't Done This In 20 Years Investor's Business Daily ...
In Article Trend: Neutral
March 7, 2024 (16:31) / "Zacks Commentary" (by Zacks Equity Research)
Edwards Lifesciences ( EW ) Up 2% Since Last Earnings Report: Can It Continue?
Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
In Article Trend: Somewhat-Bullish
March 6, 2024 (14:43) / "Zacks Commentary" (by Zacks Equity Research)
Edwards ( EW ) Gains From RESILIA's Global Adoption, TAVR Growth
With the Critical Care spin-off, Edwards (EW) is looking to pursue growth in TAVR, TMTT and Surgical, as well as new investments in interventional heart failure technologies.
In Article Trend: Somewhat-Bullish
February 29, 2024 (18:08) / "PR Newswire" (by Elanco Animal Health)
Elanco Animal Health is Executing on Plan to Deliver for Shareholders
Ancora Nominates Director Candidates Despite Elanco's Meaningful Operational Progress and Good Faith Engagement with the Investor
In Article Trend: Somewhat-Bullish
February 27, 2024 (16:40) / "Zacks Commentary" (by Zacks Equity Research)
HOLX or EW: Which Is the Better Value Stock Right Now?
HOLX vs. EW: Which Stock Is the Better Value Option?
In Article Trend: Bullish
February 27, 2024 (13:50) / "Zacks Commentary" (by Zacks Equity Research)
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
In Article Trend: Bullish
February 27, 2024 (13:45) / "Benzinga" (by Benzinga Insights)
Looking Into Edwards Lifesciences's Recent Short Interest - Edwards Lifesciences ( NYSE:EW )
Edwards Lifesciences's EW short percent of float has fallen 8.29% since its last report. The company recently reported that it has 9.96 million shares sold short, which is 1.66% of all regular shares that are available for trading.
In Article Trend: Somewhat-Bullish
February 26, 2024 (16:54) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Buy Edward Lifesciences ( EW ) Stock Now
Investors are optimistic about Edward Lifesciences' (EW) progress with the Structural Heart business and strong TAVR potential.
In Article Trend: Somewhat-Bullish
Related stocks from Healthcare sector
This website uses cookies to ensure you get the best experience on our website